This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignees: Centre Hospitalier Unviersitaire De Caen, Katholieke Universiteit Leuven, National Institute of Health and Medical Research. Active years: 2019.
Company Filing History:
1 out of 1 
1 out of 630 
1 out of 1,853 
Years Active: 2019
Title: Ann Gils: Innovator in Thrombotic Disorder Treatments
Introduction
Ann Gils is a prominent inventor based in Leuven, Belgium. She has made significant contributions to the field of medical research, particularly in the treatment of thrombotic disorders. Her innovative work has led to the development of a bispecific inhibitor that targets specific proteins involved in these conditions.
Latest Patents
Ann Gils holds a patent for her invention titled "Dual targeting of TAFI and PAI-1." This patent discloses a bispecific inhibitor designed for use in treating thrombotic disorders, including acute conditions such as stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies that target TAFI and PAI-1, demonstrating efficacy both in the presence and absence of plasminogen activators like tissue-type plasminogen activator (tPA). She has 1 patent to her name.
Career Highlights
Throughout her career, Ann Gils has worked with esteemed institutions, including the Université de Caen Basse Normandie and the National Institute of Health and Medical Research. Her research has focused on advancing therapeutic options for patients suffering from thrombotic disorders.
Collaborations
Ann has collaborated with notable colleagues in her field, including Nick Geukens and Marina Rubio. Their combined expertise has contributed to the success of her research initiatives.
Conclusion
Ann Gils is a trailblazer in the field of thrombotic disorder treatments, with her innovative patent showcasing her commitment to improving patient outcomes. Her work continues to inspire advancements in medical research and therapy.